Using hypoxia responses to improve kidney injury treatment
Harnessing hypoxia responses to treat postischemic kidney injury and inflammation
This study is looking at how the body’s natural response to low oxygen can help protect your kidneys from damage when they’re injured, and it’s exploring new ways to improve kidney healing and function after such injuries.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10840862 on NIH RePORTER |
What this research studies
This research investigates how the body's response to low oxygen levels can be harnessed to treat acute kidney injury (AKI) caused by ischemia. It focuses on the role of Hypoxia-Inducible Factors (HIF) and their impact on metabolic pathways, particularly how they can protect kidney cells from damage and inflammation. By exploring the effects of certain metabolites, like kynurenine and kynurenic acid, the research aims to uncover new therapeutic strategies that could enhance kidney repair and function after injury.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients who have experienced acute kidney injury due to ischemia, particularly those hospitalized with this condition.
Not a fit: Patients with chronic kidney disease or those whose kidney injury is not related to ischemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve recovery outcomes for patients suffering from acute kidney injury.
How similar studies have performed: Other research has shown promising results in utilizing metabolic pathways for kidney protection, suggesting that this approach could be a significant advancement in treatment.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Kapitsinou, Pinelopi P. — Northwestern University at Chicago
- Study coordinator: Kapitsinou, Pinelopi P.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.